<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36372">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633046</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14224049</org_study_id>
    <nct_id>NCT02633046</nct_id>
  </id_info>
  <brief_title>Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS</brief_title>
  <acronym>PODOCYTE</acronym>
  <official_title>Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A 2 Part Prospective Study of H.P. Acthar® Gel (PODOCYTE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, multiple dose study to examine the effect of H.P. Acthar® Gel (repository
      corticotropin injection) in adult subjects with idiopathic focal segmental
      glomerulosclerosis (FSGS) who have failed to achieve remission with, or who are intolerant
      of, 1 or more previous immunosuppressive therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete and partial remission of proteinuria at Week 24.</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Number of subjects with complete remission (uPCR ≤ 300 mg/g) + number of subjects with partial remission (uPCR ≤ 3500 mg/g but &gt;300 mg/g and 50% reduction from baseline) at Week 24 (Visit 8)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Idiopathic Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Acthar 80 U 3x/week Open Label Treatment Period</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Starting at Week 0-23, open label treatment with Acthar 80 U 3x/week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acthar 80 U 2x/week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starting at Week 26 for subjects who meet remission criteria at Week 23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 80 U 2x/week</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Starting at Week 26 for subjects who meet remission criteria at Week 23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acthar 80 U 3x/week Open Label Extension</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Starting at Week 26 for subjects who do not achieve remission at Week 23, an additional 24 weeks of open label treatment with Acthar 80 U 3x/week will be available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar 80 U 2x/week</intervention_name>
    <description>Acthar 80 U 2x/week</description>
    <arm_group_label>Acthar 80 U 2x/week</arm_group_label>
    <other_name>H.P. Acthar® Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo 80 U 2x/week</intervention_name>
    <description>Placebo 80 U 2x/week</description>
    <arm_group_label>Placebo 80 U 2x/week</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar 80 U 3x/week</intervention_name>
    <description>Acthar 80 U 3x/week</description>
    <arm_group_label>Acthar 80 U 3x/week Open Label Treatment Period</arm_group_label>
    <arm_group_label>Acthar 80 U 3x/week Open Label Extension</arm_group_label>
    <other_name>H.P. Acthar® Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects must meet all of the following criteria for inclusion in the study at the
        Screening Visit/Visit 1 and the Baseline Visit/Visit 2.

          1. Subjects must be adequately informed and understand the nature and risks of the study
             and must be able to provide a signature and date on the ICF.

          2. Subjects must be ≥ 18 years of age at Screening Visit/Visit 1 and can be male or
             female.

          3. Female subjects must be of nonchildbearing potential (history of hysterectomy,
             bilateral oophorectomy, or are postmenopausal with no history of menstrual flow in
             the 12 months prior to Screening Visit/Visit 1), or if of childbearing potential must
             be nonpregnant, nonlactating and agree to use effective contraception with a male
             partner throughout study participation and for 4 weeks after ending study
             participation. Acceptable forms of contraception include hormonal measures (oral
             contraceptive pills, contraceptive patch, contraceptive ring, injections),
             intrauterine devices, double barrier method (condom plus diaphragm, condom or
             diaphragm plus spermicidal gel or foam), and abstinence.

          4. Male subjects with a female partner of childbearing potential must have been
             surgically sterilized (vasectomy) or agree to use a double barrier for contraception
             (condom plus diaphragm, condom or diaphragm plus spermicidal gel or foam) or remain
             abstinent throughout their study participation and for 4 weeks after ending study
             participation.

          5. Subjects must have a history of primary FSGS confirmed by a renal biopsy ≤ 3 years
             prior to Screening Visit/Visit 1; or subjects must have a history of primary FSGS
             confirmed by biopsy performed between 3 to 5 years prior to Screening Visit/Visit 1
             and, in the investigator's opinion, the subject has no signs or symptoms of other
             clinical diagnoses that could suggest a change in renal histology. Approval by the
             medical monitor (MM) is required prior to enrollment if renal biopsy was done 3 to 5
             years prior to the Screening Visit/Visit 1.

          6. Subjects must have a total urine protein creatinine ratio (uPCR) &gt; 3500 mg/g(396
             mg/mmol) at Screening Visit/Visit 1.

          7. Subjects must have an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
             at the Screening Visit/Visit 1 as calculated by the 4-variable modification of diet
             in renal disease (MDRD) study equation.

          8. Subjects must have failed to achieve sustained CR or PR of proteinuria as determined
             by the investigator with ≥ 1 prior immunosuppressive therapy, or must have
             intolerance to ≥ 1 prior immunosuppressive therapy.

          9. Subjects must have been treated with an ACEi, ARB, or DRI for ≥ 4 weeks prior to
             Screening Visit/Visit 1 and on stable maintenance dose(s) for ≥ 14 days prior to
             Screening Visit/Visit 1 and are expected to remain on that dose for the duration of
             the study or have a documented intolerance to angiotensin converting enzyme inhibitor
             (ACEi), angiotensin receptor blocker (ARB), or direct renin inhibitor (DRI) with
             approval from the MM prior to enrollment. Subjects taking other antihypertensive
             medication(s), must be on a stable dose for ≥ 4 weeks prior to the Screening
             Visit/Visit 1.

         10. Subjects must have a mean systolic blood pressure ≤ 150 mm Hg and a diastolic blood
             pressure of ≤ 90 mm Hg determined by the average of ≥ 3 seated readings taken at
             least 5 minutes apart at Screening Visit/Visit 1 and at the Baseline Visit/Visit 2.

         11. Subjects must be able to communicate effectively with study personnel.

         12. Subjects must be able and willing to follow all protocol requirements and study
             restrictions.

         13. Subjects must be able and willing to return for all study visits.

        Exclusion Criteria

        Subjects are ineligible for study participation if they meet any of the following criteria
        at the Screening Visit/Visit 1 or Baseline Visit/Visit 2.

          1. Subject is from a vulnerable population, as defined by the US CFR Title 45, Part 46,
             Section 46.111(b) and other local and national regulations, including but not limited
             to, employees (temporary, part-time, full time, etc) or a family member of the
             research staff conducting the study, or of the sponsor, or of the clinical research
             organization, or of the IRB/IEC.

          2. Subject is unwilling to receive, or is intolerant of, subcutaneous injections.

          3. Subject has any history of use of ACTH preparations for treatment of nephrotic
             syndrome (including but not limited to Acthar and Synacthen®).

          4. Subject has a history of sensitivity to ACTH preparations (including but not limited
             to Acthar and Synacthen).

          5. Subject has a history of sensitivity to porcine protein products.

          6. Subject has a body mass index (BMI) &gt; 45 kg/m2 at Screening Visit/Visit 1.

          7. Subject has secondary FSGS, including but not limited to, obesity, known genetic
             cause, reduced kidney mass, Human Immunodeficiency Virus (HIV), intravenous heroin
             abuse, or sickle cell anemia.

          8. Subject has had a renal biopsy demonstrating &gt; 50% global glomerular senescence, or &gt;
             50% cortical interstitial fibrosis, or collapsing FSGS.

          9. Subject has any known contraindication(s) to Acthar (Mallinckrodt ARD, 2015)
             including, but not limited to:

               -  Any known history of scleroderma, osteoporosis, or ocular herpes simplex.

               -  Any current uncontrolled hypertension, primary adrenocortical insufficiency, or
                  adrenal cortical hyperfunction.

               -  Any current congestive heart failure (defined as New York Heart Association
                  Functional Class III to IV).

               -  Peptic ulcer (within 6 months prior to Screening Visit/Visit 1).

               -  Recent major surgery (within 6 months prior to Screening Visit/Visit 1, renal
                  biopsy is not considered an exclusionary surgical procedure).

         10. Subject has a history of chronic active hepatitis; active or chronic hepatitis B; or
             acute or chronic hepatitis C.

         11. Subject has a history of tuberculosis (TB) infection, any signs/symptoms of TB, or
             any close contact with an individual with an active TB infection.

         12. Subject has a clinically significant infection requiring intravenous administration
             of antibiotics and hospitalization in the 4 weeks prior to Screening Visit/Visit 1.

         13. Subject has known immune compromised status, including but not limited to,
             individuals who have undergone organ transplantation or who are known to be positive
             HIV.

         14. Subject has Type 1 or Type 2 diabetes mellitus (prior diagnosis of gestational
             diabetes mellitus is not exclusionary).

         15. Subject has had any of the following in the 12 weeks prior to Screening Visit 1/Visit
             1:

             unstable angina confirmed by a cardiologist, myocardial infarction, coronary artery
             bypass graft, percutaneous trans-luminal coronary angioplasty, transient ischemic
             attack or cerebrovascular disease, unstable cardiac arrhythmia, or resuscitated
             sudden cardiac death.

         16. Subject has any solid tumor malignancy currently diagnosed or undergoing therapy, or
             has received therapy for any solid tumor malignancy in the 5 years prior to Screening
             Visit/Visit 1, with the exception of treated and cured basal cell carcinoma, treated
             and cured squamous cell carcinoma of the skin, and treated and cured carcinoma in
             situ of the cervix.

         17. Subject has a diagnosis of, is undergoing therapy for, or has received therapy for a
             hematologic malignancy in the 5 years prior to Screening Visit/Visit 1.

         18. Subject has had treatment with any prohibited medications within the specified
             timeframe prior to the Screening Visit/Visit 1.

         19. Subject has had treatment with any prohibited medications within a specified
             timeframe prior to Baseline Visit/Visit 2.

         20. Subject has current or recent (within 6 months of the Screening Visit/Visit 1) drug
             or alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders,
             Fifth Edition, Diagnostic Criteria for Drug and Alcohol Abuse (American Psychiatric
             Association, 2013).

         21. Subject has any of the following laboratory abnormalities at the Screening
             Visit/Visit1 :

               -  Hemoglobin ≤ 8.0 g/dL.

               -  Platelets ≤ 50,000 cells/µL.

               -  Absolute neutrophil count (ANC) ≤ 1000 cells/µL.

               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total
                  bilirubin &gt; 2 times upper limit of normal (ULN).

               -  Glycosylated hemoglobin (HbA1c) &gt;7.5%.

               -  Positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody
                  (HBcAb).

               -  Positive Hepatitis C virus antibody (HCV) and HCV polymerase chain reaction
                  (PCR) ≥ 25 IU/mL (HCV PCR will be automatically analyzed if HCV is positive).

               -  Positive or indeterminate interferon gamma release assay (IGRA).

         22. Subject has any other clinically significant disease, disorder or laboratory
             abnormality.

         23. Subjects cannot have failed to achieve remission on 2 or more prior immunosuppressive
             therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Addie Ruffins</last_name>
    <phone>908-238-6829</phone>
    <email>addie.rufffins@mallinckrodt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mallinckrodt Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 2, 2016</lastchanged_date>
  <firstreceived_date>December 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSGS</keyword>
  <keyword>primary FSGS</keyword>
  <keyword>idiopathic FSGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
